Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (968)	11/20/1997 10:29:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 2173

>>I don't quite follow your logic in your post. You think pramlintide will eventually be approved and Type I is a large market, but somehow AMLN will still go down to $4. You believe AMLN is dead money or worse for quite a while here, but you will buy it anyway if it goes down to $4. I must have missed something here. I think to short AMLN is a better way to make money if you really believe yourself.<< Try reading my post again without twisting my words. When I said dead money or worse, I meant that it might well stay at these levels or even go a bit lower for a while. As it did today. I never said it would go down to 4. However, if it did, I believe it would be a good value at that price and I would be a buyer. I would not short it as I believe it is reasonably priced here given the uncertainty and long time periods until there is certainty. I do think pramlintide will ultimately be approved for Type 1, otherewise I would not buy the stock at any price. What you "missed" was what you misinterpreted. I take no pleasure in giving shareholders of an ailing stock a hard time. I have owned enough myself.